A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models
To make up for the limitations of previous prognostic models, we developed and validated a model in patients with metastatic or recurrent gastric adenocarcinoma (AGC), and to compare with previous models.
A total of 2,805 patients received chemotherapy for AGC in Asan Medical Center between January 2000 and December 2008 and were randomly split into training and validation sets of 1,870 and 935 patients, respectively. A prognostic model was developed from the training set.
The median follow-up duration was 26.5 months (range, 10.8–116.3), during which time 2,495 patients (88.9%) died. Eight factors associated with poor prognosis were identified by multivariate analysis: ECOG performance status ≥2 (2 points), no gastrectomy, peritoneal metastasis, bone metastasis (2 points), lung metastasis, alkaline phosphatase > 120 IU/l, albumin < 3.3 g/dL, and total bilirubin > 1.2 mg/dL. A prognostic model was developed by dividing patients into good (0–1 points), moderate (2–3), and poor (≥4) risk groups. The overall survival (OS) curves for three risk groups differed significantly for both the training and the validation sets (P < 0.001 each). In the training set, the median OS for the three risk groups was 14.0, 9.4, and 5.1 months, respectively. Application of three previous prognostic models to our validation set showed that the four models, including ours, had similar ability to predict survival outcomes (c-statistics, 0.5520–0.5836).
Validation and comparison of prognostic models indicated that our model was as effective as the previous models to stratify the patients with AGC.
KeywordsStomach neoplasms Prognosis Tumor burden Chemotherapy Validation studies
- 2.Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE (2010) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev (3):CD004064Google Scholar
- 5.Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén P-O, Haglund U, Svensson C, Enander L-K, Linné T, Sellsröm H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8(2):163–168PubMedCrossRefGoogle Scholar
- 7.Kang Y-K, Kang W-K, Shin D-B, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20(4):666–673. doi:10.1093/annonc/mdn717 PubMedCrossRefGoogle Scholar
- 8.Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse M-L, Ajani JA (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the v325 study group. J Clin Oncol 24(31):4991–4997. doi:10.1200/jco.2006.06.8429 PubMedCrossRefGoogle Scholar
- 9.Lee SS, Lee J-L, Ryu M-H, Chang HM, Kim TW, Kang H-J, Kim WK, Lee JS, Kang Y-K (2007) Combination chemotherapy with capecitabine (x) and cisplatin (p) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol 37(1):30–37PubMedCrossRefGoogle Scholar
- 11.Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22(12):2395–2403. doi:10.1200/Jco.2004.08.154 PubMedCrossRefGoogle Scholar
- 12.Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, Park JO, Park YS, Lim HY, Sohn TS, Noh JH, Heo JS, Park CK, Kim S, Kang WK (2007) Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 18(5):886–891. doi:10.1093/annonc/mdl501 PubMedCrossRefGoogle Scholar
- 15.Yoshida M, Ohtsu A, Boku N, Miyata Y, Shirao K, Shimada Y, Hyodo I, Koizumi W, Kurihara M, Yoshida S, Yamamoto S (2004) Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the japan clinical oncology group (JCOG) study. Jpn J Clin Oncol 34(11):654–659PubMedCrossRefGoogle Scholar
- 22.Cho BC, Jeung HC, Choi HJ, Rha SY, Hyung WJ, Cheong JH, Noh SH, Chung HC (2007) Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute. J Surg Oncol 95(6):461–468. doi:10.1002/jso.20731 PubMedCrossRefGoogle Scholar
- 26.Y Kang, A Ohtsu, E Van Cutsem, SY Rha, A Sawaki, S Park, H Lim, J Wu, B Langer, Shah MA (2010) AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 28 (7 suppl):abstr LBA4007Google Scholar
- 28.Bouvier A-M, Sant M, Verdecchia A, Forman D, Damhuis R, Willem Coebergh J, Crocetti E, Crosignani P, Gafa L, Launoy G, Martinez-Garcia C, Plesko I, Pompe-Kirn V, Rachtan J, Velten M, Vercelli M, Zwierko M, Esteve J, Faivre J (2010) What reasons lie behind long-term survival differences for gastric cancer within Europe? Eur J Cancer 46(6):1086–1092. doi:10.1016/j.ejca.2010.01.019 PubMedCrossRefGoogle Scholar
- 34.Anne-Marie B, Milena S, Arduino V, David F, Ronald D, Jan Willem C, Emanuele C, Paolo C, Lorenzo G, Guy L, Carmen M-G, Ivan P, Vera P-K, Jadwiga R, Michel V, Marina V, Maria Z, Jacques E, Jean F (2010) What reasons lie behind long-term survival differences for gastric cancer within Europe? European journal of cancer (Oxford, England: 1990) 46(6):1086–1092Google Scholar
- 36.Kanagavel D, Pokataev IA, Fedyanin MY, Tryakin AA, Bazin IS, Narimanov MN, Yakovleva ES, Garin AM, Tjulandin SA (2010) A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol. doi:10.1093/annonc/mdq032